GGrantIndex
Sort

23,748 grants matching melanoma

ERK Signaling in Inflammatory Bone Loss

$357,978
Francis Young-In Lee · Columbia University Health Sciences · R01 · FY2010 · AR

Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells

$357,915
Jose Alejandro Guevara-Patino · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA

Characterizing oncogenic function of ITCH in melanoma

$357,913
Lixin Wan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA

Core C: Survey Shared Resource Core

$357,871
Jessica Chubak · Kaiser Foundation Research Institute · P01 · FY2020 · CA

Using Clonal and Non-Clonal UV Signature Mutations to Predict Skin Cancer Risk

$357,871
Douglas E Brash · Yale University · R01 · FY2023 · CA

Role of the SWI/SNF complex in tumor suppression

$357,826
Charles W Roberts · St. Jude Children'S Research Hospital · R01 · FY2017 · CA

Targeting TIGIT and PD-1 in Melanoma

$357,804
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA

IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA

$357,719
University Of Southern California · R01 · FY2003 · CA

Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape

$357,712
Yuhang Zhang · University Of Cincinnati · R01 · FY2022 · CA

Developing therapeutic strategies for ERK-dependent tumors

$357,666
Neal Rosen · Sloan-Kettering Inst Can Research · R01 · FY2014 · CA

Project 2: Mechanochemical Mechanisms and Vulnerabilities of Individual and Collective Organ-Preferential Metastasis In Vivo

$357,662
Peter Friedl · Massachusetts Institute Of Technology · U54 · FY2024 · CA

Training Program in Cancer Immunobiology

$357,553
Bradley W McIntyre · University Of Tx Md Anderson Can Ctr · T32 · FY2006 · CA

CLASS II ANTIGEN PRESENTATION VIA CHAPERONE MEDIATED AUTOPHAGY

$357,512
Janice S Blum · Indiana University Indianapolis · R01 · FY2014 · AI

Impact of Endogenous DOPA Signaling on Melanocyte Homeostasis and Melanoma Susceptibility

$357,500
Todd W Ridky · University Of Pennsylvania · R56 · FY2021 · AR

Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy

$357,393
John Tanner Wilson · Vanderbilt University · R01 · FY2023 · CA

Biogenesis of Melanosomes

$357,263
Seth J. Orlow · New York University School Of Medicine · R01 · FY2008 · AR

Lymph Node Alterations in Cancer

$357,254
M Alanna Ruddell · Fred Hutchinson Cancer Research Center · R01 · FY2011 · CA

Defining critical aspects of environmental ultraviolet exposure in melanogenesis

$357,247
Myles G Cockburn · University Of Southern California · R01 · FY2011 · ES

Defining critical aspects of environmental ultraviolet exposure in melanogenesis

$357,247
Myles G Cockburn · University Of Southern California · R01 · FY2012 · ES

The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells

$357,238
Edmund K. Moon · University Of Pennsylvania · R01 · FY2019 · CA

Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma Progression

$357,230
Amanda W. Lund · New York University School Of Medicine · U54 · FY2024 · CA

Transcriptional mechanisms and melanoma

$357,175
Leonard I Zon · Massachusetts General Hospital · P01 · FY2022 · CA

Transcriptional mechanisms and melanoma

$357,170
Leonard I Zon · Massachusetts General Hospital · P01 · FY2023 · CA

Tumor Neovasculature Vector Targeting

$357,167
Sidney Kimmel Cancer Center · R21 · FY2002 · CA

Combining senescence-inducing and senolytic agents to improve melanoma therapy

$357,067
Anna E Vilgelm · Ohio State University · R37 · FY2020 · CA